首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2676285篇
  免费   208899篇
  国内免费   8473篇
耳鼻咽喉   34859篇
儿科学   88132篇
妇产科学   72954篇
基础医学   374317篇
口腔科学   76139篇
临床医学   242081篇
内科学   531793篇
皮肤病学   62591篇
神经病学   213564篇
特种医学   104975篇
外国民族医学   504篇
外科学   412196篇
综合类   63601篇
现状与发展   6篇
一般理论   902篇
预防医学   206820篇
眼科学   61266篇
药学   193304篇
  11篇
中国医学   5856篇
肿瘤学   147786篇
  2018年   29339篇
  2017年   22522篇
  2016年   25624篇
  2015年   29049篇
  2014年   40485篇
  2013年   60118篇
  2012年   78920篇
  2011年   83987篇
  2010年   50934篇
  2009年   48357篇
  2008年   78026篇
  2007年   83115篇
  2006年   84405篇
  2005年   81093篇
  2004年   77991篇
  2003年   74872篇
  2002年   71722篇
  2001年   134593篇
  2000年   138175篇
  1999年   114644篇
  1998年   32216篇
  1997年   28296篇
  1996年   27536篇
  1995年   28474篇
  1994年   26399篇
  1993年   24554篇
  1992年   90528篇
  1991年   87866篇
  1990年   84732篇
  1989年   81206篇
  1988年   74585篇
  1987年   73236篇
  1986年   68979篇
  1985年   65960篇
  1984年   49423篇
  1983年   41686篇
  1982年   24665篇
  1981年   22103篇
  1980年   20446篇
  1979年   43919篇
  1978年   31078篇
  1977年   26436篇
  1976年   24490篇
  1975年   25683篇
  1974年   30644篇
  1973年   29516篇
  1972年   27442篇
  1971年   25233篇
  1970年   23298篇
  1969年   21867篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
42.

Objectives

To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.

Design

Cross-sectional survey.

Method

An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.

Results

Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.

Conclusions

Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy.  相似文献   
43.
44.
45.
Graefe's Archive for Clinical and Experimental Ophthalmology - The published online version contains mistake as the author's first name and last name have been interchanged as "Hild...  相似文献   
46.
47.
48.
Coronary embolism (CE) is an uncommon and unique cause of acute myocardial infarction. In this report, we review 216 cases of CE including 2 new cases from our institution. The mean patient age was 52.5 years and 62% of the patients were males. Chest pain was the most common presenting symptom followed by dyspnea, and the most commonly affected vessel was the left anterior descending artery. Leading etiologies of the embolus were atrial fibrillation, septic emboli, and iatrogenic causes. Treatment approaches varied with thrombus aspiration being used in 30% of cases. In-hospital mortality rate was 36% and 13% of the cases were complicated by cerebrovascular accident. CE is a unique pathology that leads to acute myocardial infarction. It portends a high mortality rate and requires a high level of suspicion as symptoms may be misleading. Further research is needed in order to improve recognition and management and to lower associated mortality.  相似文献   
49.
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity.  相似文献   
50.
International Journal of Mental Health and Addiction - One of the relatively new negative consequences of smartphone use is “phubbing” (snubbing someone while an individual checks their...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号